Eyram Adjogatse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eyram Adjogatse has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan B. Cooper
Division of Medicine, UCL, Gower Street, London WC1E 6BT, England
2 shared publications - Peter T. Erskine
Division of Medicine, UCL, Gower Street, London WC1E 6BT, United Kingdom
2 shared publications - Steve Wood
Division of Medicine, University College London, Gower Street, London WC1E 6BT, England
2 shared publications - Ah Wing Edith Chan
Wolfson Institute of Biomedical Research, University College London, Gower Street, London WC1E 6BT, UK
1 shared publication - Alun R. Coker
Division of Medicine, University College London, Gower Street, London WC1E 6BT, England
1 shared publication - Brendan William Wren
Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK
1 shared publication
Latest Publications
- 28 July 2021
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section F Structural Biology Communications
- Vol. 77 (8) , 269-274
The X-ray structure ofL-threonine dehydrogenase from the common hospital pathogenClostridium difficile
In many prokaryotes, the first step of threonine metabolism is catalysed by the enzyme threonine dehydrogenase (TDH), which uses NAD+to oxidize its substrate to 2-amino-3-ketobutyrate. The absence of a functional TDH gene in humans suggests that inhibitors of this enzyme may have therapeutic potential against pathogens which are reliant on this enzyme. Here, TDH fromClostridium difficilehas been cloned and overexpressed, and the X-ray structure of the apoenzyme form has been determined at 2.6 Å resolution.
- 28 July 2021
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section F Structural Biology Communications
- Vol. 77 (8) , 269-274
The X-ray structure ofL-threonine dehydrogenase from the common hospital pathogenClostridium difficile
In many prokaryotes, the first step of threonine metabolism is catalysed by the enzyme threonine dehydrogenase (TDH), which uses NAD+to oxidize its substrate to 2-amino-3-ketobutyrate. The absence of a functional TDH gene in humans suggests that inhibitors of this enzyme may have therapeutic potential against pathogens which are reliant on this enzyme. Here, TDH fromClostridium difficilehas been cloned and overexpressed, and the X-ray structure of the apoenzyme form has been determined at 2.6 Å resolution.
- 1 September 2018
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section D Structural Biology
- Vol. 74 (9) , 861-876
Structure and function ofL-threonine-3-dehydrogenase from the parasitic protozoanTrypanosoma bruceirevealed by X-ray crystallography and geometric simulations
Two of the world's most neglected tropical diseases, human African trypanosomiasis (HAT) and Chagas disease, are caused by protozoan parasites of the genusTrypanosoma. These organisms possess specialized metabolic pathways, frequently distinct from those in humans, which have potential to be exploited as novel drug targets. This study elucidates the structure and function of L-threonine-3-dehydrogenase (TDH) fromT. brucei, the causative pathogen of HAT. TDH is a key enzyme in the metabolism of L-threonine, and an inhibitor of TDH has been shown to have trypanocidal activity in the procyclic form ofT. brucei. TDH is a nonfunctional pseudogene in humans, suggesting that it may be possible to rationally design safe and specific therapies for trypanosomiasis by targeting this parasite enzyme. As an initial step, the TDH gene fromT. bruceiwas expressed and the three-dimensional structure of the enzyme was solved by X-ray crystallography. In multiple crystallographic structures,T. bruceiTDH is revealed to be a dimeric short-chain dehydrogenase that displays a considerable degree of conformational variation in its ligand-binding regions. Geometric simulations of the structure have provided insight into the dynamic behaviour of this enzyme. Furthermore, structures of TDH bound to its natural substrates and known inhibitors have been determined, giving an indication of the mechanism of catalysis of the enzyme. Collectively, these results provide vital details for future drug design to target TDH or related enzymes.
- 1 September 2018
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section D Structural Biology
- Vol. 74 (9) , 861-876
Structure and function ofL-threonine-3-dehydrogenase from the parasitic protozoanTrypanosoma bruceirevealed by X-ray crystallography and geometric simulations
Two of the world's most neglected tropical diseases, human African trypanosomiasis (HAT) and Chagas disease, are caused by protozoan parasites of the genusTrypanosoma. These organisms possess specialized metabolic pathways, frequently distinct from those in humans, which have potential to be exploited as novel drug targets. This study elucidates the structure and function of L-threonine-3-dehydrogenase (TDH) fromT. brucei, the causative pathogen of HAT. TDH is a key enzyme in the metabolism of L-threonine, and an inhibitor of TDH has been shown to have trypanocidal activity in the procyclic form ofT. brucei. TDH is a nonfunctional pseudogene in humans, suggesting that it may be possible to rationally design safe and specific therapies for trypanosomiasis by targeting this parasite enzyme. As an initial step, the TDH gene fromT. bruceiwas expressed and the three-dimensional structure of the enzyme was solved by X-ray crystallography. In multiple crystallographic structures,T. bruceiTDH is revealed to be a dimeric short-chain dehydrogenase that displays a considerable degree of conformational variation in its ligand-binding regions. Geometric simulations of the structure have provided insight into the dynamic behaviour of this enzyme. Furthermore, structures of TDH bound to its natural substrates and known inhibitors have been determined, giving an indication of the mechanism of catalysis of the enzyme. Collectively, these results provide vital details for future drug design to target TDH or related enzymes.